Clinical Image

A Rare Plasma Cell Dyscrasiain Paraspinal Muscles Shown by 18F-FDG PET/CT

Elgin Ozkan*
Department of Nuclear Medicine, Ankara University, Turkey


*Corresponding author: Elgin Ozkan, Department of Nuclear Medicine, Ankara University, Ankara, Turkey


Published: 13 Feb, 2017
Cite this article as: Ozkan E. A Rare Plasma Cell Dyscrasiain Paraspinal Muscles Shown by 18F-FDG PET/CT. Clin Oncol. 2017; 2: 1202.

Clinical Image

F-18 fluorodeoxyglucose (FDG) PET/CT is a highly influential workup that provides valuable information inplasma cell dyscrasia. In this case, we report 51 years old male with plasma cell dyscrasia, who referred for F-18 FDG PET/CT as part of a reevaluation workup, with diffuse increased paraspinal skeletal muscle uptake. Additionally 18F – FDG PET/CT disclosed right supradiaphragmatic and retrocrural lymph node and 1th sacral vertebra metastases.

Figure 1

Another alt text

Figure 1
A 51-year-old male with plasma cell dyscrasia was referred for F-18 FDG PET/CT to evaluate metabolic response to 6 cycle of chemotherapy with sisplatin, siklofosfamid, etoposid and deksametazon. Maximal Intensity Projection (MIP) view (a) andcoronal PET view (b) showed diffuse increased unilateral paraspinal skeletal muscle, right supradiaphragmatic and retrocrural lymph nodes and 1th sacral vertebra uptake. The maximal standardized uptake values (SUVmax) of the paraspinal muscle, right supradiaphragmatic lymph nodes, retrocrural lymph nodes, 1th sacral vertebra metastases and pleural effusion were 6.6, 5.5, 5.9, 11.6, 3.0 respectively. Right paraspinal muscle uptake was seen between 1st thoracal and 5th lumbar vertebra level.

Figure 2

Another alt text

Figure 2
(a) Axial views shows pleural effusion and right paraspinal muscle uptake. (b) Retrocrural lymph nodes and right paraspinal muscle uptake. (c) Sacral 1st vertebra metastases.

References

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, CA Cancer J Clin. 2015; 65: 5-29.
  2. Ghaneh P, Costello E, Neoptolemos JP. Biology and management of pancreatic cancer. Gut. 2007; 56: 1134-1152.
  3. Chu GC, Kimmelman AC, Hezel AF, DePinho RA. Stromal biology of pancreatic cancer. J Cell Biochem. 2007; 101: 887-907.
  4. Erkan M, Hausmann S, Michalski CW, Fingerle AA, Dobritz M, Kleeff J, et al. The role of stroma in pancreatic cancer: diagnostic and therapeutic implications. Nat Rev GastroenterolHepatol. 2012; 9: 454-467.
  5. Bissell MJ, Radisky D. Putting tumours in context. Nat Rev Cancer. 2001; 1: 46-54.
  6. Miyamoto H, Murakami T, Tsuchida K, Sugino H, Miyake H, Tashiro S. Tumor-stroma interaction of human pancreatic cancer: acquired resistance to anticancer drugs and proliferation regulation is dependent on extracellular matrix proteins. Pancreas. 2004; 28: 38-44.
  7. Park CC, Bissell MJ, Barcellos-Hoff MH. The influence of the microenvironment on the malignant phenotype. Mol Med Today. 2000; 6: 324-329.
  8. Mahadevan D, Von Hoff DD. Tumor-stroma interactions in pancreatic ductal adenocarcinoma. Mol Cancer Ther. 2007; 6: 1186-1197.
  9. Grzesiak JJ, Bouvet M. The alpha2beta1 integrin mediates the malignant phenotype on type I collagen in pancreatic cancer cell lines. Br J Cancer. 2006; 94: 1311-1319.
  10. Pucci-Minafra I, Luparello C, Andriolo M, Basiricò L, Aquino A, Minafra S. A new form of tumor and fetal collagen that binds laminin. Biochemistry. 1993; 32: 7421-7427.
  11. Pucci-Minafra I, Albanese NN, Di Cara G, Minafra L, Marabeti MR, Cancemi P. Breast cancer cells exhibit selective modulation induced by different collagen substrates. Connect Tissue Res. 2008; 49: 252-256.
  12. Luparello C, Sirchia R. Type V collagen regulates the expression of apoptotic and stress response genes by breast cancer cells. J Cell Physiol. 2005; 202: 411-421.
  13. Souza P, Rizzardi F, Noleto G, Atanazio M, Bianchi O, Parra ER, et al. Refractory remodeling of the microenvironment by abnormal type V collagen, apoptosis, and immune response in non-small cell lung cancer. Hum Pathol. 2010; 41: 239-248.
  14. Ignotz RA, Massagué J. Transforming growth factor-beta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J Biol Chem. 1986; 261: 4337-4345.
  15. Binkley CE, Zhang L, Greenson JK, Giordano TJ, Kuick R, Misek D, et al. The molecular basis of pancreatic fibrosis: common stromal gene expression in chronic pancreatitis and pancreatic adenocarcinoma. Pancreas. 2004; 29: 254-263.
  16. Bertrand P, Girard N, Delpech B, Duval C, d'Anjou J, Dauce JP. Hyaluronan (hyaluronic acid) and hyaluronectin in the extracellular matrix of human breast carcinomas: comparison between invasive and non-invasive areas. Int J Cancer. 1992; 52: 1-6.
  17. Whatcott CJ, Diep CH, Jiang P, Watanabe A, LoBello J, Sima C, et al. Desmoplasia in Primary Tumors and Metastatic Lesions of Pancreatic Cancer. Clin Cancer Res. 2015; 21: 3561-3568.
  18. Duda DG, Duyverman AM, Kohno M, Snuderl M, Steller EJ, Fukumura D, et al. Malignant cells facilitate lung metastasis by bringing their own soil. Proc Natl Acad Sci U S A. 2010; 107: 21677-21682.
  19. Rhim AD, Oberstein PE, Thomas DH. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell. 2014; 25: 735-747.
  20. Özdemir BC, Pentcheva-Hoang T, Carstens JL, Zheng X, Wu CC, Simpson TR, et al. Depletion of carcinoma-associatedfibroblasts and fibrosisinducesimmunosuppression and accelerates pancreas cancer with reducedsurvival. Cancer Cell. 2014; 25: 719-734.
  21. Froeling FE, Kocher HM. Homeostatic restoration of desmoplastic stroma rather than its ablation slows pancreatic cancer progression. Gastroenterology. 2015; 14: 849-850.
  22. Carapuça EF, Gemenetzidis E, Feig C, Bapiro TE, Williams MD, Wilson AS, et al. Anti-stromal treatment together with chemotherapy targets multiple signalling pathways in pancreatic adenocarcinoma. J Pathol. 2016; 239: 286-296.